Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
133 hedge funds and large institutions have $633M invested in Taro Pharmaceutical Industries Ltd. in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 46 increasing their positions, 41 reducing their positions, and 15 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 41
5% less funds holding
Funds holding: 140 → 133 (-7)
6% less capital invested
Capital invested by funds: $671M → $633M (-$38.2M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
99% less call options, than puts
Call options by funds: $36K | Put options by funds: $2.43M
Top Buyers
| 1 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$18.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.05M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.78M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$2.38M |
| 5 |
Goldman Sachs
New York
|
+$2.11M |
Top Sellers
TARO Hedge Fund Activity: Q3 2017 in Review
133 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2017, worth a combined $633M — down 5.7% from $671M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TARO and 8 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 46 added.
The largest buyer was AJO LP, adding an estimated $18.1M. The largest seller was Carmignac Gestion, exiting entirely with an estimated $16.5M sold.
- 133 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2017, down from 140 in Q2 2017.
- Funds reported $633M of Taro Pharmaceutical Industries Ltd. stock for Q3 2017, down 5.7% quarter-over-quarter.
- 8 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2017 and 15 closed out, a net change of -7 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2017 was AJO LP, an estimated $18.1M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2017 was Carmignac Gestion, an estimated $16.5M sold.
Based on aggregated 13F filings for Q3 2017.